Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 2;2015(11):CD009420.
doi: 10.1002/14651858.CD009420.pub3.

Levomepromazine for nausea and vomiting in palliative care

Lalage Cox  1 , Emily Darvill, Saskie Dorman
Affiliations

Levomepromazine for nausea and vomiting in palliative care

Lalage Cox et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the original Cochrane Review published in Issue 4, 2013, on Levomepromazine for nausea and vomiting in palliative care.Nausea and vomiting are common, distressing symptoms for patients receiving palliative care. There are several drugs which can be used to treat these symptoms, known as antiemetics. Levomepromazine is an antipsychotic drug is commonly used as an antiemetic to alleviate nausea and vomiting in palliative care settings.

Objectives: To evaluate the efficacy of, and adverse events associated with, levomepromazine for the treatment of nausea and vomiting in palliative care patients.

Search methods: For this update we searched electronic databases, including those of Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, up to February 2015. We searched clinical trial registers on 7 October 2015 for ongoing trials.

Selection criteria: Randomised controlled trials of levomepromazine for the treatment of nausea or vomiting, or both, in adults receiving palliative care. We excluded studies in which symptoms were thought to be due to pregnancy or surgery.

Data collection and analysis: We assessed the potential relevance of studies based on titles and abstracts. We obtained copies of any study reports that appeared to meet the inclusion criteria for further assessment. At least two review authors read each paper to determine suitability for inclusion and discussed discrepancies in order to achieve a consensus.

Main results: In the original review, we identified 421 abstracts using the search strategy. We considered eight studies for inclusion but ultimately excluded them all from the review. We updated the search in February 2015 and identified 35 abstracts, but again none met the inclusion criteria. We identified two trials from clinical trial registers, one of which is ongoing and one of which was closed due to poor recruitment.

Authors' conclusions: As in the initial review, we identified no published randomised controlled trials examining the use of levomepromazine for the management of nausea and vomiting in adults receiving palliative care, and our conclusion (that further studies of levomepromazine and other antiemetic agents are needed to provide better evidence for their use in this setting) remains unchanged. We did, however, identify one ongoing study that we hope will contribute to the evidence base for this intervention in future updates of this review.

PubMed Disclaimer

Conflict of interest statement

LC has no conflict of interest to declare. SD has no conflict of interest to declare. ED has no conflict of interest to declare.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Amesbury 2004 {published data only}
    1. Amesbury B, Alloway L, Hickmore E, Dewhurst G. High‐dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome. Journal of Palliative Care 2004;20(2):117‐8. - PubMed
Baines 1985 {published data only}
    1. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet 1985;2(8462):990‐993. - PubMed
Benze 2012 {published data only}
    1. Benze G, Alt‐Epping B, Geyer A, Nauck F. Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients: a review. Der Schmerz 2012;26(5):500‐14. - PubMed
Dietz 2013 {published data only}
    1. Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliative Care 2013;12. [DOI: ] - PMC - PubMed
Eisenchlas 2005 {published data only}
    1. Eisenchlas JH, Garrigue N, Junin M, Simone GG. Low‐dose levomepromazine in refractory emesis in advanced cancer patients: an open‐label study. Palliative Medicine 2005;19(1):71‐5. - PubMed
Ell 1983 {published data only}
    1. Ell C, Konig H, Gutmann W, Domschke S, Domschke W. Prevention of cytostatic‐induced vomiting. High‐dosage metoclopramide versus an antiemetic combination in a controlled comparison [Prophylaxe von zytostatika‐bedingtem Erbrechen. Hochdosiertes Metoclolpramid versus Antiemetika‐Kombination im kontrollierten Vergleich]. Die Medizinische Welt 1983;34(35):945‐8. - PubMed
Gordon 2014 {published data only}
    1. Gordon P, LeGrand SB, Walsh D. Nausea and vomiting in advanced cancer. European Journal of Pharmacology 2014;722:187‐91. - PubMed
Higi 1980 {published data only}
    1. Higi M, Niederle N, Schmidt C, Seeber S. Improved antiemetic treatment with levomepromazine [Verbesserte antiemetische Behandlung mit Levomepromazin bei zyotstatikabedingtem Erbrechen]. Deutsche Medizinische Wochenschrift 1980;105(22):794‐5. - PubMed
Kennett 2004 {published data only}
    1. Kennett A, Hardy J, Shah S, A'Hern R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Supportive Care in Cancer 2005;13(9):715‐21. - PubMed
McCabe 2003 {published data only}
    1. McCabe HL, Maraveyas A. Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy‐induced emesis (DCIE). Anticancer Research 2003;23(6D):5209‐12. - PubMed
Sgouros 2003 {unpublished data only}
    1. Sgouros J, Neville‐Webb H, Bunton S, Lind M, Maraveyas A. Levomepromazine versus dexamethasone with metoclopramide in the prevention of cisplatin induced delayed emesis. Preliminary results of a randomised study. British Journal of Cancer 2003;88:S68.
Twycross 1997 {published data only}
    1. Twycross RG, Barkby DG, Hallwood PM. The use of low dose levomepromazine (methotrimeprazine) in the management of nausea and vomiting. Progress in Palliative Care 1997;5(2):49‐53.

References to ongoing studies

ACTRN12615000177550 {published data only}
    1. Hardy J. A study for participants with cancer who experience ongoing nausea, not related to their treatment, despite taking standard and usual medications, that studies the effectiveness of oral methotrimeprazine versus oral haloperidol. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=1261... (accessed 17 August 2015).

Additional references

ACTRN12610000482066
    1. Hardy, J, Yates P. ACTRN12610000482066 [Randomised controlled trial: The effectiveness of alternative antiemetic therapies in patients with cancer and nausea not related to cancer therapy]. The Australian New Zealand Clinical Trials Registry (ANZCTR) 2010.
Bentley 2001
    1. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting: a prospective audit. Palliative Medicine 2001;15(3):247‐53. - PubMed
Dahl 1977
    1. Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. European Journal of Clincal Pharmacology 1977;11(4):305‐10. - PubMed
Davis 2010
    1. Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of Pain and Symptom Management 2010;39(4):756‐67. - PubMed
Douglas 2009
    1. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced kidney disease: a review of the literature and development of evidence‐based guidelines by a United Kingdom Expert Consensus Group. Palliative Medicine 2009;23(2):103‐10. - PubMed
EAPC 2010
    1. European Association for Palliative Care. Definition of palliative care (English). http://www.eapcnet.eu/Corporate/AbouttheEAPC/Definitionandaims.aspx (accessed 17 August 2015).
Edmonds 2001
    1. Edmonds P, Karlsen S, Khan S, Addington‐Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001;15(4):287‐95. - PubMed
Glare 2004
    1. Glare P, Pereira G, Kristjanson L, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far‐advanced cancer. Supportive Care in Cancer 2004;12(6):432‐40. - PubMed
Grande 2000
    1. Grande GE, Todd CJ. Why are trials in palliative care so difficult?. Palliative Medicine 2000;14(1):69‐74. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hirst 2001
    1. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003346] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Keeley 2009
    1. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clinical Evidence 2009;2009:2406. - PMC - PubMed
Klinkenberg 2004
    1. Klinkenberg M, Willems DL, Wal G, Deeg DJ. Symptom burden in the last week of life. Journal of Pain and Symptom Management 2004;27(1):5‐13. - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24.
Perkins 2009
    1. Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006271.pub2] - DOI - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Skinner 1999
    1. Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer. Hospital Medicine 1999;60(8):568‐70. - PubMed
Stephenson 2006
    1. Stephenson J, Davies A. An assessment of aetiology‐based guidelines for the management of nausea and vomiting in patients with advanced cancer. Supportive Care in Cancer 2006;14(4):348‐53. - PubMed
Storrar 2014
    1. Storrar J, Hitchens M, Platt T, Dorman S. Droperidol for treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD006938.pub3] - DOI - PMC - PubMed
Twycross 1998
    1. Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5:39‐45.
Twycross 2014
    1. Twycross R, Wilcock A, Howard P (editors). Palliative Care Formulary. 5th Edition. Palliativedrugs.com Ltd, 2014.
Wee 2008
    1. Wee B, Hadley G, Derry S. How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews. BMC Palliative Care 2008;7. [doi:10.1186/1472‐684X‐7‐13] - PMC - PubMed

References to other published versions of this review

Darvill 2013
    1. Darvill E, Dorman S, Perkins P. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD009420.pub2] - DOI - PubMed

Publication types